Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 13/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139511 | 0.86 | WDR5 (0.47) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL13648676 | 0.83 | PTGIR (0.53) | WDR5ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL32665951 | 0.83 | LMNA (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL29315350 | 0.83 | LMNA (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560664 | 0.80 | LMNA (0.56) | LMNANISCHGAAAPOBEC3ACTDSP1 | |
| SCHEMBL17186490 | 0.76 | PTGIR (0.61) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL956651 | 0.75 | HTR1D (0.57) | LMNANISCHADRA2AADRA2BADRA2C | |
| Flutonidine SCHEMBL352837 | 0.75 | ADRA2A (0.63) | NISCHADRA2AADRA2BADRA2CADRA1D | |
| Flutonidine SCHEMBL29367926 | 0.75 | ADRA2A (0.63) | NISCHADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL10022889 | 0.75 | LMNA (0.62) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075981-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | LMNA 2007/4885NISCH 4840/4885GAA 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.